AACR report calls for US cancer funding to be a national priority

18 September 2014
aacr-big

Declining budgets have slowed the pace of research into cancer, according to a new report from the American Association for Cancer Research (AACR).

The AACR 2014 Cancer Progress Report found that while research continues to provide significant advances against cancer, spurred by investments in the National Institutes of Health (NIH) and National Cancer Institute (NCI), the pace of progress is being slowed by declining budgets. It calls on the administration and Congress to prioritize the growth of the NIH and NCI budgets at a predictable pace by providing annual budget increases, which are at least comparable to the biomedical inflation rate.

Carlos Arteaga, president of the AACR and professor of medicine and cancer biology at Vanderbilt-Ingram Cancer Center, Vanderbilt University, Nashville, Tennessee, said: “While we are continuing to make impressive progress against cancer, the pace of that progress is being slowed due to years of declining budgets at the NIH and NCI. If we are to fully realize the promise of science to transform cancer care, it will require leadership in Congress and within the administration to ensure that biomedical research in cancer becomes a major priority for our nation."

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight





More Features in Pharmaceutical